摘要
目的观察益生菌制剂对轻、中度溃疡性结肠炎的临床疗效。方法第一阶段将129例轻、中度溃疡性结肠炎患者随机分成治疗组(65例)和对照组(64例),分别予以益生菌和美拉沙嗪治疗,治疗12周后观察两组缓解率及缓解时间。第二阶段将缓解后91例患者随机分成治疗组(43例)和对照组(48例),分别予以益生菌和美拉沙嗪治疗,治疗12周后观察两组维持时间及复发率。结果第一阶段两组患者治疗后缓解率及达到临床缓解时间无明显统计学差异(P>0.05);第二阶段两组患者治疗后维持缓解时间及复发率无明显统计学差异(P>0.05)。结论益生菌能够有效治疗轻、中度活动性溃疡性结肠炎,并有效预防复发。
Objective To observe the clinical effects of probiotics drug in the treatment of mild and moderate ulcerative colitis, Methods Total 129 patients with mild to moderate active ulcerative colitis were divided into treatment group （65 patients） and control group （64 patients） at first stage, the former were treated with probiotics drug, the later were treated with mesalazine, the study lasted for 12 weeks and patients were assessed by clinical remission rate and the time to clinical remission. At second stage 91 patients in remission of ulcerative colitis were radomized into two groups to receive probiotics drug （43 patients in treatment group ） or mesalazine （48 patients in control group）. After 12 months relapse - free time and relapse rate were determined. Results At first stage,after 12 weeks treatment there were no statistical differences （ P 〉 0. 05 ） between treatment group and control group in clinical remission rate and the time to clinical remission. At second stage, there were no differences between two groups （ P 〉 0.05 ） in relapse - free time and relapse rate. Conclusion Probiotics drug are effective in treatment of mild and moderate active ulcerative colitis and preventing relapse.
出处
《医药论坛杂志》
2007年第24期52-54,共3页
Journal of Medical Forum
关键词
益生菌
美拉沙嗪
轻
中度溃疡性结肠炎
Probiotics
Mesalazine
Mild and moderate ulcerative colitis
